SIMULATIONS PLUS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 50.95 USD | +1.48% |
|
+5.40% | +13.85% |
Presenter SpeechRenee Bouche (Executives)Good afternoon. It is Monday, July 10, 2017. And on b...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Simulations Plus, Inc. is a provider of modeling and simulation software and services for pharmaceutical drug discovery and development, including the prediction of properties of molecules utilizing both artificial intelligence and machine-based technology. The Company's segments include software and services. It offers 12 software products for pharmaceutical research and development: GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, MonolixSuite, ADMET Predictor and MedChem Designer. Its services include population pharmacokinetic and pharmacodynamic, quantitative systems pharmacology/quantitative systems toxicology, and physiologically based pharmacokinetic. The Company provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions supporting product approval. Its software and consulting services are provided to various industries, including biotechnology and cosmetics.
Calendar
09/07/2024
- Q3 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
50.95
USD
Average target price
53.67
USD
Spread / Average Target
+5.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.85% | 1.02B | |
| +9.22% | 33.98B | |
| +21.99% | 8.16B | |
| +31.37% | 4.26B | |
| -30.15% | 2.65B | |
| -19.11% | 1.4B | |
| -28.03% | 1.27B | |
| -33.21% | 1.17B | |
| -34.50% | 917M | |
| -24.11% | 660M |
- Stock Market
- Equities
- SLP Stock
- News Simulations Plus, Inc.
- Transcript : Simulations Plus, Inc., Q3 2017 Earnings Call, Jul 10, 2017
